AARD
Aardvark Therapeutics, Inc. Common StockAARD
AARD
About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
–
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
123%
upside
Avg. target
$31
224%
upside
High target
$50
431%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target | 123%upside $21 | Outperform Initiated | 10 Mar 2025 |
Cantor Fitzgerald Josh Schimmer 24% 1-year accuracy 13 / 54 met price target | 431%upside $50 | Overweight Initiated | 10 Mar 2025 |
Morgan Stanley Michael Ulz 17% 1-year accuracy 3 / 18 met price target | 208%upside $29 | Overweight Initiated | 10 Mar 2025 |
B of A Securities Tim Anderson 38% 1-year accuracy 5 / 13 met price target | 134%upside $22 | Buy Initiated | 10 Mar 2025 |
Financial journalist opinion
Neutral
24/7 Wall Street
1 month ago
Biotechs Highlight 6 Stocks Insiders Are Buying Now
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
Neutral
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week
Seven IPOs and three SPACs were listed this week. Seven IPOs and four SPACs submitted initial filings. Some small IPOs are tentatively scheduled for the short holiday week ahead.
Neutral
GlobeNewsWire
1 month ago
Aardvark Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,888,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aardvark. The gross proceeds to Aardvark from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $94.2 million. Aardvark's common stock is expected to begin trading on the Nasdaq Global Select Market on February 13, 2025 under the ticker symbol “AARD.” The offering is expected to close on February 14, 2025, subject to the satisfaction of customary closing conditions. In addition, Aardvark has granted the underwriters a 30-day option to purchase up to an additional 883,200 shares of common stock at the public offering price, less underwriting discounts and commissions.
Positive
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial Group, and Huachen AI Parking Management Technology. Eight IPOs are currently scheduled to list in the week ahead, although some small issuers may also join the calendar throughout the week.
Positive
Seeking Alpha
1 month ago
Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments
Aardvark Therapeutics aims to raise $100 million in an IPO to fund its clinical-stage biopharma treatments for metabolic conditions, including Prader-Willi syndrome. Its lead candidate ARD-101, targeting hyperphagia, is entering Phase 3 trials with topline data expected in early 2026. The PWS market is projected to exceed $1 billion by 2034, presenting significant growth potential despite its rarity.
Charts implemented using Lightweight Charts™